Common name
3-ethyl-1,1-dimethyl-urea
IUPAC name
3-ethyl-1,1-dimethyl-urea
SMILES
CN(C(=O)NCC)C
Common name
3-ethyl-1,1-dimethyl-urea
IUPAC name
3-ethyl-1,1-dimethyl-urea
SMILES
CN(C(=O)NCC)C
INCHI
InChI=1S/C5H12N2O/c1-4-6-5(8)7(2)3/h4H2,1-3H3,(H,6,8)
FORMULA
C5H12N2O
Common name
3-ethyl-1,1-dimethyl-urea
IUPAC name
3-ethyl-1,1-dimethyl-urea
Molecular weight
116.162
clogP
-0.748
clogS
-0.729
Frequency
0.0003
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
32.34
Number of Rings
0
Rotatable Bond
2
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01652 | Cobicistat |
|
Anti-HIV Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
1 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 2yix_ligand_2_0.mol2 | 2yix | 1 | -6.28 | CCNC(=O)NC | 7 |
| 4x6n_ligand_3_40.mol2 | 4x6n | 1 | -5.80 | C(=O)(NCC)NC | 7 |
| 4x6m_ligand_3_37.mol2 | 4x6m | 1 | -5.77 | C(NC(=O)NC)C | 7 |
| 2fw3_ligand_3_238.mol2 | 2fw3 | 1 | -5.75 | CNC(=O)NCC | 7 |
122 ,
13
